LDS/Medical Tests/Long QT Syndrome Multi-Gene Panel, NGS

Long QT Syndrome Multi-Gene Panel, NGS

The ‘Cardiac Ion Channelopathies’ panel detects mutation in genes associated with cardiac channelopathies. These are a group of heritable ion channel disorders that are associated with cardiac arrhythmias and sudden cardiac death in the presence of a structurally normal heart. These disorders have been associated with mutations in genes that encode cardiac ion channel subunits or proteins that interact with, and regulate, ion channels. Cardiac channelopathies that effect the Na+-ion channel include Brugada syndrome (BrS), long QT syndrome (LQTS), short QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Certain mutations can give rise to different phenotypes with enhanced or reduced channel function and even combinations of phenotypes. Affected individuals have a structurally normal heart but an increased risk of syncope and sudden cardiac death (SCD) caused by ventricular tachycardia (VT) or ventricular fibrillation (VF).

Long QT syndrome (LQTS)

LQTS is a cardiac channelopathy characterized by a QT segment prolongation and can result in ventricular tachyarrhythmias with associated episodes of syncope and SCD. LQTS is one of the leading causes of SCD among young people. It can be congenital or acquired, the latter is generally associated with drugs and electrolyte imbalances (hypokalemia, hypocalcemia, and hypomagnesemia). The clinical presentation can be variable, ranging from asymptomatic to episodes of syncope and SD caused by ventricular tachyarrhythmias (torsade de pointes). Prolongation of the QT interval may arise because of a decrease in the K+ repolarization currents or to an inappropriate delay in the entry of Na+ into the myocyte. 10–15% of the LQTS cases are related to mutations in SCN5A (Type 3 LQTS). Individuals with Type 3 LQTS present arrhythmias associated with bradycardia and symptoms at rest, especially during sleep. Type 3 LQT patients do not respond as well to β-blockers, and the presence of a long QT3 mutation is a sign of high risk for cardiac events. LQTS Type 10 is caused by a mutation in the SCN4B gene, which encodes the β4-subunit of the cardiac Na+ channel (Nav4b). This mutation induces a positive change in the inactivation of Na+ channels, which increases Na+ current and delays the repolarization in a similar fashion to Type 3 LQTS. Genetic testing in LQTS can detect an underlying mutation in 60–70% of patients.

Short QT syndrome (SQTS)

SQTS is a clinically malignant entity characterized by a short QT interval (<330 milliseconds), with tall, symmetric and peaked T waves leading to ventricular arrhythmias and the potential for SCD in the neonatal period. Most patients have a family history of SCD with an autosomal dominant pattern of transmission and high penetrance. Type 1 SQTS has been associated with the KCNH2 gene (human-ether-a-go-go-related gene), which induces a fast activation of K+ currents, and shortened ventricular action potentials. SQTS Type 2 has been linked to mutations in the KCNQ1 gene. while SQTS Type 3 is caused by a mutation in KCNJ2 gene which accelerates the Phase 3 of the cardiac action potential. This latter form of short QT has a characteristic ECG pattern, described as an abrupt and sharp termination of the T wave.

Panel Components

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: AKAP9, ANK2, CASQ2, CAV3, CACNA1C, CAV3, CACNA2D1, GPD1L, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNQ1, RYR2, SCN4B, SNTA1, SCN3B, CACNB2, SCN1B, and SCN5A associated with Cardiac Ion Channelopathies.

  • Aid in the diagnosis of long QT syndrome, short QT syndrome
  • Providing a genetic evaluation for patients with a personal or family history of unexplained sudden cardiac death
  • For appropriate management and surveillance for disease features based on the gene involved
  • Identification of a pathogenic variant may assist with prognosis, clinical management, familial screening, and genetic counseling

Depending in variation (been small intragenic deletions/insertions and missense, nonsense, and splice site variants) if pathogenic and if associated with or loss or decreased function of the phenotype related to disease will be more indicative or diagnostic.

Simply, the evidence must support a pathogenic classification of genes variation (mutation) tested to be diagnostic or prognostic as well as therapy target. Note: some of the gene variants tested by this panel may have more than one associated phenotype changes and/or inheritance pattern. In contrast, some genetic variants may have reduced penetrance and/or variable expressivity in some phenotypic individuals.

Negative for pathogenic variations (mutations), deletions and insertions for tested genes

Target Next-generation sequencing (NGS) and supplemental Sanger sequencing, multiplex ligation probe amplification (MLPA) can be used to test for the presence of large deletions and duplications in a subset of genes.

Whole blood (EDTA), buccal swab (alternative).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Brugada Syndrome Multi-Gene Panel, Blood, Cardiac Ion Channelopathies Multi-Gene Panel, NGS, Hypertrophic cardiomyopathy (HCM), Cardiomyopathy and Arrhythmia Panel, Sequencing and Deletion/Duplication.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login